Cathie Wood’s ARK ETFs have disclosed their daily trades for Friday, March 14th, 2025, with significant transactions across a variety of sectors.
The most substantial trade of the day came from the sale of UIPATH INC (NYSE:PATH), with ARK’s ARKK and ARKW ETFs parting with a combined 1,250,919 shares, resulting in a cash influx of approximately $12.47 million. This move continues a recent trend for ARK, which has been reducing its position in UIPATH consistently over the past week.
In contrast, ARK has increased its stake in GITLAB INC (NASDAQ:GTLB), purchasing 104,153 shares split between ARKK and ARKW ETFs, amounting to an investment of over $5.2 million. This acquisition aligns with ARK’s strategy, as they also expanded their holdings in GITLAB on the previous Thursday.
ARK also bought 79,201 shares of IBOTTA INC (NASDAQ:IBTA) across its ARKW and ARKF ETFs, with a total value of approximately $3.17 million. Notably, this purchase adds to ARK’s ongoing accumulation of IBOTTA shares, as seen in several recent trading sessions.
Another key transaction involved INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), where ARK bought a total of 67,520 shares through ARKK and ARKG ETFs, injecting around $622,534 into the gene-editing company.
On the sell side, ARK divested 47,153 shares of CAREDX INC (NASDAQ:CDNA) through its ARKG ETF for about $831,778, and 46,026 shares of PRIME MEDICINE INC (NASDAQ:PRME) through ARKK ETF, totaling approximately $79,164.
The sale of 38,757 shares of ROBLOX CORP (NYSE:RBLX) across ARKW and ARKF ETFs brought in nearly $2.16 million, while ARK’s ARKG ETF sold 53,449 shares of REPARE THERAPEUTICS INC (NASDAQ:RPTX) for around $59,862.
ARK’s daily trade reports continue to offer insights into the investment firm’s strategic decisions, providing investors with a glimpse into the thinking of one of the industry’s most closely watched fund managers. As always, market participants will be watching to see how these trades align with long-term trends and the evolving ARK investment thesis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.